BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC)

Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: dc103135592cc5bf004f815e5c0c823652773cf3
First added on: May 16, 2026